Comparison of Antibiotic Susceptibility of Carbapanem-Resistant Enterobactericeae Species with Two Different Panels (Phoenix BD)-Reference-Cited by-同舟云学术

Comparison of Antibiotic Susceptibility of Carbapanem-Resistant Enterobactericeae Species with Two Different Panels (Phoenix BD)

Published:2022-03-30 Issue: Volume: Page:
ISSN:1303-6610
Container-title:Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
language:tr
Short-container-title:KSÜ Tıp Fak Der

Author:

UĞURLU Hacer¹,KÜÇÜK Burak²,ORAK Filiz¹,ARAL Murat¹

Affiliation:

1. KAHRAMANMARAŞ SÜTÇÜ İMAM ÜNİVERSİTESİ, TIP FAKÜLTESİ

2. Kahramanmaras Sütcü Imam University

Abstract

Objective: The aim of this study; The aim of this study is to compare the antibiotic susceptibility of carbapanem-resistant Enterobactericeae strains isolated in the microbiology laboratory of our hospital with two different panels and to evaluate the performance of the CPO test. Material & Method: The samples sent to the microbiology laboratory of our hospital between 01.01.2020 - 31.12.2020 were evaluated. Specimens with growth were loaded onto the BD Phoenix 100 automated system BD Phoenix NMIC 433 panel, and 50 isolates of Enterobacteriaceae that resulted in carbapenem resistant were studied with the BD Phoenix NMIC 505 CPO panel. 50 carbapenem-resistant Enterobacteriaceae isolates were classified according to Ambler class A, B, and D by the CPO panel. Results: Of the isolates, 28 (56%) were isolated from male patients and 22 (44%) from female patients. Of the carbapenem-resistant Enterobacteriaceae isolates, 43 (86%) were identified as Klebsiella pneumoniae and 4 (8%) were Escherichia coli. When the evaluation of antibiotic susceptibility rates of the CPO panel and NMIC 433 panel of carbapenem-resistant Enterobacteriaceae isolates were examined; Antibiotic susceptibility results of 50 Enterobacteriaceae isolates studied in both panels were found to be the same. When the antibiotics that can be studied in the CPO panel were examined, it was observed that the most effective antibiotic was ceftazidime-avibactam. When the results were examined, it was observed that 46 (92%) isolates were susceptible to ceftazidime-avibactam. The number of bacteria producing class B carbapenemase was 4 (8%) and the number of bacteria producing class D carbapenemase was 42 (84%). Conclusion: It should be noted that ceftazidime avibactam can be used as a treatment option in carbapenem-resistant species. Further work on the CPO panel will help identify the contribution of the CPO panel to the routine workflow.

Publisher

Kahramanmaras Sutcu Imam Universitesi Tip Fakultesi Dergisi

Subject

General Medicine

Reference23 articles.

1. 1. Taşova Y. Gram negatif enterik bakteri infeksiyonlarının yönetimi. Ankem Derg. 2011;25(2):33-44.

2. 2. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17(10):1791-8.

3. 3. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical microbiology reviews. 2001;14(4):933-51.

4. 4. Castanheira M, Farrell SE, Krause KM, Jones RN, Sader HS. Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine US census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups. Antimicrobial agents and chemotherapy. 2014;58(2):833-8.

5. 5. Ehmann DE, Jahić H, Ross PL, Gu R-F, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor. Proceedings of the National Academy of Sciences. 2012;109(29):11663-8.